StockNews.AI
GMAB
StockNews.AI
141 days

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

1. Genmab's TIVDAK receives EU marketing authorization for advanced cervical cancer. 2. This is the first ADC approved for recurrent or metastatic cervical cancer.

2m saved
Insight
Article

FAQ

Why Bullish?

The approval of TIVDAK may significantly boost GMAB's revenue potential, similar to historical drug approvals that led to stock surges.

How important is it?

The article discusses a significant milestone in drug approval, likely to influence GMAB's valuation directly.

Why Long Term?

Successful market penetration of TIVDAK could enhance GMAB's growth trajectory over several years, akin to the impact seen with other successful drug therapies.

Related Companies

ABBVPFEMRNA
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) has granted marketing authorization for TIVDAK® (tisotumab vedotin), an antibody-drug conjugate (ADC), as monotherapy treatment for adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy. TIVDAK is the first and only ADC to be granted European Union (EU) marketing authorization for people living with recurrent or metastatic.

Related News